Osteal Therapeutics
David Thompson President & CEO

Osteal Therapeutics is a privately held, clinical-stage biopharmaceutical company developing novel combination therapeutics to treat orthopedic infections and their consequences.  The company is leveraging the ability of highly concentrated, locally delivered antimicrobials to kill the bacterial biofilms typically responsible for musculoskeletal infections.  This enables rapid resolution of infection while minimizing off-target tissue exposure and associated adverse effects.  Osteal employs a low-risk development strategy by using approved drugs with long histories of safety and efficacy as candidates for new routes of local delivery.